GHRS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 20:56):

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders...

Stats
Dzisiejszy wolumen	24 042.00
Średni wolumen	121 515
Kapitalizacja rynkowa	613.41M
EPS	$0 ( 2024-03-07 )
Następna data zysków	( $-0.220 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-17.34
ATR14	$0.0600 (0.51%)

Wolumen Korelacja

Długi: -0.12 (neutral)

Krótki: -0.29 (neutral)

Signal:(54.917) Neutral

GH Research PLC Korelacja

10 Najbardziej pozytywne korelacje
DAVE	0.979
GRCL	0.974
LGAC	0.965
USLM	0.964
HERA	0.964
ABGI	0.963
AGGR	0.962
GXII	0.962
ACQR	0.962
HERAU	0.962

10 Najbardziej negatywne korelacje
QNRX	-0.976
ALHC	-0.966
BNRG	-0.966
FWRD	-0.964
PRTS	-0.964
LPSN	-0.958
BGFV	-0.958
RGF	-0.957
SSTI	-0.957
APTO	-0.956

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GH Research PLC Korelacja - Waluta/Towar

0.49
( neutral )

0.22
( neutral )

0.64
( weak )

0.47
( neutral )

0.02
( neutral )

-0.50
( neutral )

GH Research PLC Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-315 000 (0.00 %)
EPS:	$-0.680

FY	2023
Przychody:	$0
Zysk brutto:	$-315 000 (0.00 %)
EPS:	$-0.680

FY	2022
Przychody:	$0
Zysk brutto:	$-47 000.00 (0.00 %)
EPS:	$-0.140

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.211

Financial Reports:

No articles found.

GH Research PLC

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Aktualne aktualizacje dla GH Research PLC [GHRS]

Upcoming Earnings Alert